RedHill Biopharma Secures Allowance of Key Chinese Patent Application for Proprietary COVID-19 Treatment, RHB-107 Apr 28, 2025 07:03AM
RedHill Biopharma (RDHL) Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study Apr 24, 2024 07:02AM
RedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study Apr 24, 2024 07:00AM
RedHill and U.S. Army Announce Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic Effect Against Ebola Dec 20, 2023 08:45AM
RedHill Biopharma (RDHL) Announces New, Non-Dilutive External Funding of Entire RHB-107 COVID-19 300-Patient Phase 2 Study Dec 4, 2023 07:05AM


Dec 4, 2023 07:00AM RedHill Announces New, Non-Dilutive External Funding of Entire RHB-107 COVID-19 300-Patient Phase 2 Study
Jul 31, 2023 07:01AM RedHill Biopharma's (RDHL) RHB-107 Included in U.S. Government-Supported COVID-19 Platform Trial
Jul 31, 2023 07:00AM RedHill's RHB-107 Included in U.S. Government-Supported COVID-19 Platform Trial and Cleared for Initiation by FDA
Jan 3, 2023 07:00AM RedHill Announces Publication of Positive Phase 2 Study Results with Once-Daily Oral RHB-107 in Non-Hospitalized COVID-19
Oct 3, 2022 07:00AM RedHill's Oral Broad-Acting Antivirals, Opaganib and RHB-107, Inhibit Dominant Omicron Sub-Variant BA.5
Jul 12, 2022 08:00AM RedHill Announces New H. pylori and COVID-19 Data Publication and Presentations at Leading Upcoming Scientific Conferences
Mar 1, 2022 09:00AM RedHill Announces Positive Phase 2 Study Results with Oral RHB-107 in Non-Hospitalized COVID-19
Dec 6, 2021 07:00AM RedHill Biopharma Reports that Opaganib Mechanism Not Impacted by Viral Spike-Protein Mutations, Including Omicron Mutations
Nov 15, 2021 07:00AM RedHill Biopharma Announces Last Patient Randomized in Part A of Ongoing Phase 2/3 COVID-19 Study of Once-Daily Oral RHB-107 in Non-Hospitalized Patients
Sep 13, 2021 07:00AM RedHill Biopharma Accelerates Ongoing U.S. Phase 2/3 COVID-19 Study of Once-Daily Oral RHB-107 in Non-Hospitalized Patients with South African Approval
May 26, 2021 07:05AM RedHill Biopharma (RDHL) Receives Allowances for U.S. Patent Applications Covering Opaganib and RHB-107 for COVID-19
May 26, 2021 07:00AM RedHill Biopharma Receives Allowances for U.S. Patent Applications Covering Opaganib and RHB-107 for COVID-19
Feb 17, 2021 07:00AM RedHill Biopharma Announces First Patient Dosed in U.S. Phase 2/3 COVID-19 Outpatient Study with RHB-107